• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Decrease of carbapenemase-producing Enterobacteriaceae incidence during the first year of the COVID-19 pandemic.

作者信息

Duverger Clarisse, Monteil Catherine, Souyri Valérie, Fournier Sandra

机构信息

Assistance Publique-Hôpitaux de Paris, Central Infection Prevention and Control Team, 3 avenue Victoria, Paris 75004, France.

Assistance Publique-Hôpitaux de Paris, Central Infection Prevention and Control Team, 3 avenue Victoria, Paris 75004, France.

出版信息

J Infect. 2022 Jul;85(1):90-122. doi: 10.1016/j.jinf.2022.03.024. Epub 2022 Apr 1.

DOI:10.1016/j.jinf.2022.03.024
PMID:35378141
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8971063/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c890/8971063/4214355b7436/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c890/8971063/f50967ef1c98/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c890/8971063/4214355b7436/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c890/8971063/f50967ef1c98/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c890/8971063/4214355b7436/gr2_lrg.jpg

相似文献

1
Decrease of carbapenemase-producing Enterobacteriaceae incidence during the first year of the COVID-19 pandemic.2019年冠状病毒病大流行第一年期间，产碳青霉烯酶肠杆菌科细菌发病率下降。
J Infect. 2022 Jul;85(1):90-122. doi: 10.1016/j.jinf.2022.03.024. Epub 2022 Apr 1.
2
Occurrence of carbapenemase-producing Enterobacteriaceae in Togo, West Africa.西非多哥产碳青霉烯酶肠杆菌科细菌的出现情况。
Int J Antimicrob Agents. 2019 Apr;53(4):530-532. doi: 10.1016/j.ijantimicag.2018.11.019. Epub 2018 Nov 24.
3
Combination therapy for bloodstream infections with carbapenemase-producing Enterobacteriaceae.产碳青霉烯酶肠杆菌科细菌血流感染的联合治疗
Lancet Infect Dis. 2017 Oct;17(10):1020. doi: 10.1016/S1473-3099(17)30521-2.
4
Combination therapy for bloodstream infections with carbapenemase-producing Enterobacteriaceae - Authors' reply.产碳青霉烯酶肠杆菌科细菌血流感染的联合治疗——作者回复
Lancet Infect Dis. 2017 Oct;17(10):1020-1021. doi: 10.1016/S1473-3099(17)30522-4.
5
Carbapenemase-Producing Enterobacteriaceae and Nonfermentative Bacteria, the Philippines, 2013-2016.2013 - 2016年菲律宾产碳青霉烯酶肠杆菌科细菌和非发酵菌
Emerg Infect Dis. 2017 Sep;23(9):1597-1598. doi: 10.3201/eid2309.161237.
6
Aztreonam-Avibactam Combination Restores Susceptibility of Aztreonam in Dual-Carbapenemase-Producing Enterobacteriaceae.氨曲南-阿维巴坦联合用药恢复了产双碳青霉烯酶肠杆菌科细菌对氨曲南的敏感性。
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00414-18. Print 2018 Aug.
7
High prevalence of fecal carriage of Extended-spectrum beta-lactamase and carbapenemase-producing Enterobacteriaceae among food handlers at the University of Gondar, Northwest Ethiopia.埃塞俄比亚西北部贡德尔大学食品处理人员中产超广谱β-内酰胺酶和碳青霉烯酶肠杆菌科细菌粪便携带率高。
PLoS One. 2022 Mar 17;17(3):e0264818. doi: 10.1371/journal.pone.0264818. eCollection 2022.
8
Lack of polymyxin resistance among carbapenemase-producing Enterobacteriaceae in a university hospital in China.中国一家大学医院中产碳青霉烯酶肠杆菌科细菌对多粘菌素耐药性的缺失。
Infect Dis (Lond). 2017 Jul;49(7):556-557. doi: 10.1080/23744235.2017.1292543. Epub 2017 Mar 3.
9
Antecedent Carbapenem Exposure as a Risk Factor for Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae and Carbapenemase-Producing Enterobacteriaceae.碳青霉烯类药物暴露前史是产非碳青霉烯酶类碳青霉烯耐药肠杆菌科和产碳青霉烯酶肠杆菌科的危险因素。
Antimicrob Agents Chemother. 2019 Sep 23;63(10). doi: 10.1128/AAC.00845-19. Print 2019 Oct.
10
Duration of Carbapenemase-Producing Enterobacteriaceae Carriage in Hospital Patients.产碳青霉烯酶肠杆菌科在医院患者中的携带时间。
Emerg Infect Dis. 2020 Sep;26(9):2182-2185. doi: 10.3201/eid2609.190592.

引用本文的文献

1
Distribution and molecular characterization of carbapenemase-producing gram-negative bacteria in Henan, China.中国河南产碳青霉烯酶的革兰氏阴性菌的分布及分子特征。
Sci Rep. 2024 Jun 22;14(1):14418. doi: 10.1038/s41598-024-65106-0.
2
Distribution and Drug Resistance of Bacterial Infection in Hospitalized Patients at the Respiratory Department before and after the COVID-19 Pandemic in Guangzhou, China.中国广州 COVID-19 大流行前后呼吸内科住院患者细菌感染的分布及耐药性
Microorganisms. 2023 Oct 12;11(10):2542. doi: 10.3390/microorganisms11102542.
3
The impact of the COVID-19 pandemic on the number of hand, foot, and mouth disease due to enterovirus 71 infections.

本文引用的文献

1
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.2019 年全球细菌对抗菌药物耐药性的负担：系统分析。
Lancet. 2022 Feb 12;399(10325):629-655. doi: 10.1016/S0140-6736(21)02724-0. Epub 2022 Jan 19.
2
Surging bloodstream infections and antimicrobial resistance during the first wave of COVID-19: a study in a large multihospital institution in the Paris region.新冠疫情第一波期间血流感染和抗菌药物耐药性激增：巴黎地区一家大型多医院机构的研究。
Int J Infect Dis. 2022 Jan;114:90-96. doi: 10.1016/j.ijid.2021.10.034. Epub 2021 Oct 22.
3
Decreasing proportion of extended-spectrum beta-lactamase among E. coli infections during the COVID-19 pandemic in France.
2019年冠状病毒病大流行对肠道病毒71型感染所致手足口病病例数的影响。
J Infect. 2023 Apr;86(4):e111-e113. doi: 10.1016/j.jinf.2023.02.005. Epub 2023 Feb 9.
4
Influence of the COVID-19 pandemic on Staphylococcus aureus bloodstream infection in children, Henan, China.中国河南新冠疫情对儿童金黄色葡萄球菌血流感染的影响
J Infect. 2023 Mar;86(3):256-308. doi: 10.1016/j.jinf.2022.12.020. Epub 2022 Dec 25.
5
Changes of Haemophilus influenzae infection in children before and after the COVID-19 pandemic, Henan, China.中国河南儿童在新冠疫情前后流感嗜血杆菌感染情况的变化
J Infect. 2023 Jan;86(1):66-117. doi: 10.1016/j.jinf.2022.10.019. Epub 2022 Oct 20.
在法国 COVID-19 大流行期间，大肠杆菌感染中产生超广谱β-内酰胺酶的比例下降。
J Infect. 2021 Dec;83(6):664-670. doi: 10.1016/j.jinf.2021.09.016. Epub 2021 Sep 29.
4
The Impact of Coronavirus Disease 2019 (COVID-19) on Healthcare-Associated Infections.新型冠状病毒肺炎（COVID-19）对医院获得性感染的影响。
Clin Infect Dis. 2022 May 30;74(10):1748-1754. doi: 10.1093/cid/ciab688.
5
Could the COVID-19 pandemic aggravate antimicrobial resistance?新冠疫情会加剧抗菌药物耐药性吗？
Am J Infect Control. 2020 Sep;48(9):1129-1130. doi: 10.1016/j.ajic.2020.06.192. Epub 2020 Jun 27.
6
Acquisition of multidrug-resistant Enterobacterales during international travel: a systematic review of clinical and microbiological characteristics and meta-analyses of risk factors.国际旅行期间获得耐多药肠杆菌科细菌：临床和微生物学特征的系统评价和危险因素的荟萃分析。
Antimicrob Resist Infect Control. 2020 May 20;9(1):71. doi: 10.1186/s13756-020-00733-6.
7
Outbreak dynamics of COVID-19 in Europe and the effect of travel restrictions.欧洲新冠疫情的爆发动态及旅行限制的影响。
Comput Methods Biomech Biomed Engin. 2020 Aug;23(11):710-717. doi: 10.1080/10255842.2020.1759560. Epub 2020 May 5.
8
Clinical and virological data of the first cases of COVID-19 in Europe: a case series.欧洲首批 COVID-19 病例的临床和病毒学数据：一项病例系列研究。
Lancet Infect Dis. 2020 Jun;20(6):697-706. doi: 10.1016/S1473-3099(20)30200-0. Epub 2020 Mar 27.
9
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
10
Efficiency of different control measures for preventing carbapenemase-producing enterobacteria and glycopeptide-resistant outbreaks: a 6-year prospective study in a French multihospital institution, January 2010 to December 2015.不同控制措施预防产碳青霉烯酶肠杆菌科和耐糖肽肠球菌爆发的效率：2010 年 1 月至 2015 年 12 月法国多医院机构的一项 6 年前瞻性研究。
Euro Surveill. 2018 Feb;23(8). doi: 10.2807/1560-7917.ES.2018.23.8.17-00078.